265 related articles for article (PubMed ID: 31249224)
1. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
[TBL] [Abstract][Full Text] [Related]
2. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
3. Early clinical manifestations and laboratory findings before and after treatment of cytomegalovirus infection in kidney transplant patients.
Siddiqui WA; Al Salmi I; Jha A; Pakkyara A; Yasir M; Shaheen FAM
Saudi J Kidney Dis Transpl; 2017; 28(4):774-781. PubMed ID: 28748879
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients.
Natori Y; Humar A; Husain S; Rotstein C; Renner E; Singer L; Kim SJ; Kumar D
Transplantation; 2017 Jun; 101(6):1449-1454. PubMed ID: 27467535
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
[TBL] [Abstract][Full Text] [Related]
9. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
10. Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient.
Imamura T; Shiga T; Kinugawa K; Kato N; Endo M; Inaba T; Maki H; Hatano M; Yao A; Hirata Y; Nagai R
Int Heart J; 2012; 53(3):199-201. PubMed ID: 22790690
[TBL] [Abstract][Full Text] [Related]
11. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
Malvezzi P; Jouve T; Rostaing L
Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
[TBL] [Abstract][Full Text] [Related]
13. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
Sheng L; Jun S; Jianfeng L; Lianghui G
Clin Transplant; 2015 Jun; 29(6):555-9. PubMed ID: 25851741
[TBL] [Abstract][Full Text] [Related]
14. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
[TBL] [Abstract][Full Text] [Related]
15. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
16. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
Santos AH; Casey MJ; Xuerong W; Womer KL
Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
[TBL] [Abstract][Full Text] [Related]
17. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant.
Savvidaki E; Kazakopoulos P; Papachristou E; Karavias D; Zavvos V; Voliotis G; Kalliakmani P; Marangos M; Goumenos DS
Exp Clin Transplant; 2014 Feb; 12(1):31-6. PubMed ID: 24471721
[TBL] [Abstract][Full Text] [Related]
18. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
20. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
